Teachers Retirement System of The State of Kentucky Purchases 4,645 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Teachers Retirement System of The State of Kentucky raised its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 22.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,799 shares of the company’s stock after acquiring an additional 4,645 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Spyre Therapeutics were worth $601,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Huntington National Bank bought a new stake in Spyre Therapeutics during the fourth quarter valued at $34,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Spyre Therapeutics during the fourth quarter valued at $46,000. KLP Kapitalforvaltning AS bought a new stake in Spyre Therapeutics during the fourth quarter valued at $182,000. Arizona State Retirement System boosted its position in Spyre Therapeutics by 38.4% during the fourth quarter. Arizona State Retirement System now owns 10,115 shares of the company’s stock valued at $235,000 after acquiring an additional 2,805 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in Spyre Therapeutics during the fourth quarter valued at $242,000. Institutional investors own 80.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SYRE. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a report on Tuesday, February 18th. Leerink Partnrs raised Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, April 8th. Leerink Partners assumed coverage on Spyre Therapeutics in a research note on Tuesday, April 8th. They issued an “outperform” rating and a $45.00 price objective for the company. Wedbush restated an “outperform” rating and set a $65.00 price objective on shares of Spyre Therapeutics in a report on Monday, January 13th. Finally, Wolfe Research assumed coverage on Spyre Therapeutics in a report on Tuesday, March 18th. They set an “outperform” rating and a $27.00 price objective for the company. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $49.57.

Spyre Therapeutics Trading Up 3.8 %

Shares of Spyre Therapeutics stock opened at $14.67 on Tuesday. The stock has a fifty day simple moving average of $16.42 and a 200 day simple moving average of $23.14. Spyre Therapeutics, Inc. has a 12-month low of $10.91 and a 12-month high of $40.49. The company has a market capitalization of $884.25 million, a P/E ratio of -1.96 and a beta of 3.05.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.08. On average, analysts predict that Spyre Therapeutics, Inc. will post -4.46 EPS for the current year.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).